Dépouillements

Mood Disorders in Mothers of Children on the Autism Spectrum Are Associated with Higher Functioning Autism / Roma A. VASA in Autism Research and Treatment, (July 2012)  

Public ISBD [article]  inAutism Research and Treatment > (July 2012) . - 8 p. Titre : Mood Disorders in Mothers of Children on the Autism Spectrum Are Associated with Higher Functioning Autism Type de document : Texte imprimé et/ou numérique Auteurs : Roma A. VASA, Auteur ; Connie M. ANDERSON, Auteur ; Alison MARVIN, Auteur ; Rebecca E. ROSENBERG, Auteur ; J. Kiely LAW, Auteur ; Julia THORN, Auteur ; Geeta SARPHARE, Auteur ; Paul A. LAW, Auteur Année de publication : 2012 Article en page(s) : 8 p. Langues : Anglais (eng) Mots-clés : Trouble de l'humeur Index. décimale : PER Périodiques Résumé : Mood disorders occur more frequently in family members of individuals with autism spectrum disorders (ASD) than in the general population. There may be associations between maternal mood disorder history patterns and specific ASD phenotypes. We therefore examined the relationship between maternal mood disorders and child autism spectrum disorders in 998 mother-child dyads enrolled in a national online autism registry and database. Mothers of children with ASD completed online questionnaires addressing their child’s ASD as well as their own mood disorder history. In multivariate logistic regression models of ASD diagnoses, the odds of an Asperger disorder versus autistic disorder diagnosis were higher among those children whose mothers had a lifetime history of bipolar disorder (OR 2.11, CI 1.20, 3.69) or depression (OR 1.62, CI 1.19, 2.19). Further, maternal mood disorder onset before first pregnancy was associated with higher odds (OR 2.35, CI 1.48, 3.73) of an Asperger versus autism diagnosis among this sample of children with ASD. These data suggest that differences in maternal mood disorder history may be associated with ASD phenotype in offspring. En ligne : http://dx.doi.org/10.1155/2012/435646 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181 [article] Mood Disorders in Mothers of Children on the Autism Spectrum Are Associated with Higher Functioning Autism [Texte imprimé et/ou numérique] / Roma A. VASA, Auteur ; Connie M. ANDERSON, Auteur ; Alison MARVIN, Auteur ; Rebecca E. ROSENBERG, Auteur ; J. Kiely LAW, Auteur ; Julia THORN, Auteur ; Geeta SARPHARE, Auteur ; Paul A. LAW, Auteur . - 2012 . - 8 p. Langues : Anglais (eng) in Autism Research and Treatment > (July 2012) . - 8 p. Mots-clés : Trouble de l'humeur Index. décimale : PER Périodiques Résumé : Mood disorders occur more frequently in family members of individuals with autism spectrum disorders (ASD) than in the general population. There may be associations between maternal mood disorder history patterns and specific ASD phenotypes. We therefore examined the relationship between maternal mood disorders and child autism spectrum disorders in 998 mother-child dyads enrolled in a national online autism registry and database. Mothers of children with ASD completed online questionnaires addressing their child’s ASD as well as their own mood disorder history. In multivariate logistic regression models of ASD diagnoses, the odds of an Asperger disorder versus autistic disorder diagnosis were higher among those children whose mothers had a lifetime history of bipolar disorder (OR 2.11, CI 1.20, 3.69) or depression (OR 1.62, CI 1.19, 2.19). Further, maternal mood disorder onset before first pregnancy was associated with higher odds (OR 2.35, CI 1.48, 3.73) of an Asperger versus autism diagnosis among this sample of children with ASD. These data suggest that differences in maternal mood disorder history may be associated with ASD phenotype in offspring. En ligne : http://dx.doi.org/10.1155/2012/435646 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181

Autism: Where Genetics Meets the Immune System / Antonio M. PERSICO in Autism Research and Treatment, (July 2012)  

Public ISBD [article]  inAutism Research and Treatment > (July 2012) . - 2 p. Titre : Autism: Where Genetics Meets the Immune System Type de document : Texte imprimé et/ou numérique Auteurs : Antonio M. PERSICO, Auteur ; Judy VAN DE WATER, Auteur ; Carlos A. PARDO, Auteur Année de publication : 2012 Article en page(s) : 2 p. Langues : Anglais (eng) Mots-clés : Immunologie Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1155/2012/486359 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181 [article] Autism: Where Genetics Meets the Immune System [Texte imprimé et/ou numérique] / Antonio M. PERSICO, Auteur ; Judy VAN DE WATER, Auteur ; Carlos A. PARDO, Auteur . - 2012 . - 2 p. Langues : Anglais (eng) in Autism Research and Treatment > (July 2012) . - 2 p. Mots-clés : Immunologie Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1155/2012/486359 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181

Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism / Michael G. CHEZ in Autism Research and Treatment, (July 2012)  

Public ISBD [article]  inAutism Research and Treatment > (July 2012) . - 7 p. Titre : Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism Type de document : Texte imprimé et/ou numérique Auteurs : Michael G. CHEZ, Auteur ; Renee LOW, Auteur ; Carol PARISE, Auteur ; Tammy DONNEL, Auteur Année de publication : 2012 Article en page(s) : 7 p. Langues : Anglais (eng) Mots-clés : Lenalidomide Index. décimale : PER Périodiques Résumé : Autism affects 1 : 88 children in the United States. Familial history of autoimmune disease, autoantibodies in the serum of mothers when there is more than one autistic offspring, and neuroglial response in CSF and brain tissue in autistic patients suggest an immunological variable may be associated with this condition. Lenalidomide has the potential to invoke changes in TNF-α with less toxicity than thalidomide. This pilot study evaluated lenalidomide at reduction of TNF-α and improvement of behavior and language in children with autism with elevated TNF-α. Subjects with elevated TNF-α were given 2.5 mgs lenalidomide daily for 12-weeks. Pharmacodynamics and safety was evaluated. Changes in language and autistic behaviors after six and twelve weeks were measured. Although statistical significance was not achieved for most measures, there were trends toward improvement. After 6-weeks, mean receptive language increased: 60.67 ± 12.06 to 65.00 ± 15.10 (P = 0.11) and symptoms of autism decreased (40.75 ± 5.96 versus 38.67 ± 7.90, P = 0.068). After 12-weeks, CSF-TNF-α declined 57% ± 25% from 80.5 ± 41.03 to 38.0 ± 31.27 (P = 0.068). Serum TNF-α declined 57% (92.50 ± 68.92 to 40.25 ± 44.53 (P = 0.048). This study suggests that lenalidomide is tolerated as a treatment by children with autism and should be further studied as a potential agent for cytockine inflammation. En ligne : http://dx.doi.org/10.1155/2012/291601 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181 [article] Safety and Observations in a Pilot Study of Lenalidomide for Treatment in Autism [Texte imprimé et/ou numérique] / Michael G. CHEZ, Auteur ; Renee LOW, Auteur ; Carol PARISE, Auteur ; Tammy DONNEL, Auteur . - 2012 . - 7 p. Langues : Anglais (eng) in Autism Research and Treatment > (July 2012) . - 7 p. Mots-clés : Lenalidomide Index. décimale : PER Périodiques Résumé : Autism affects 1 : 88 children in the United States. Familial history of autoimmune disease, autoantibodies in the serum of mothers when there is more than one autistic offspring, and neuroglial response in CSF and brain tissue in autistic patients suggest an immunological variable may be associated with this condition. Lenalidomide has the potential to invoke changes in TNF-α with less toxicity than thalidomide. This pilot study evaluated lenalidomide at reduction of TNF-α and improvement of behavior and language in children with autism with elevated TNF-α. Subjects with elevated TNF-α were given 2.5 mgs lenalidomide daily for 12-weeks. Pharmacodynamics and safety was evaluated. Changes in language and autistic behaviors after six and twelve weeks were measured. Although statistical significance was not achieved for most measures, there were trends toward improvement. After 6-weeks, mean receptive language increased: 60.67 ± 12.06 to 65.00 ± 15.10 (P = 0.11) and symptoms of autism decreased (40.75 ± 5.96 versus 38.67 ± 7.90, P = 0.068). After 12-weeks, CSF-TNF-α declined 57% ± 25% from 80.5 ± 41.03 to 38.0 ± 31.27 (P = 0.068). Serum TNF-α declined 57% (92.50 ± 68.92 to 40.25 ± 44.53 (P = 0.048). This study suggests that lenalidomide is tolerated as a treatment by children with autism and should be further studied as a potential agent for cytockine inflammation. En ligne : http://dx.doi.org/10.1155/2012/291601 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=181